You are here

Article Text

Article menu
Download PDFPDF
Letters to the editor
Use of cyclosporin A as a steroid sparing agent in cystic fibrosis
  1. G K BHAL,
  2. S A MAGUIRE,
  3. I M BOWLER
  1. Department of Child Health
  2. Royal Gwent Hospital, Cardiff Road
  3. Newport, Gwent NP20 2UB, UK
  4. meeta@mbhal.freeserve.co.uk

https://doi.org/10.1136/adc.84.1.89

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Editor,—In cystic fibrosis (CF) chronic respiratory infection is countered by an intense inflammatory reaction. Systemic steroids have been shown to improve lung function and reduce morbidity in patients with CF and reduce markers of chronic inflammation1 ,2; however, there are significant side effects associated with their long term use. Low dose cyclosporin A (CyA) has been shown to be effective in the treatment of inflammatory and autoimmune diseases, corticosteroid dependent chronic severe asthma in adults, and refractory childhood asthma.3

    We report six …

    View Full Text